September 2026 half-year: revenue up 33%, profit up 44%; exceptional gain lifts standalone

Revenue Growth 20pctPat Growth 25pctExceptional ItemRelated Party TransactionsNegative Operating CashflowResults View source PDF Explain this filing

BLISSGVS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.3%Reaction day

₹680.90

prior close

₹660.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 173sector-0.8%-3.5% vs sector

On the reaction day the stock moved 3.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.0

10m

+1.5

15m

-1.5

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.3pendingpending-0.8-3.5

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Unaudited September 2026 results: consolidated revenue was Rs 31,336.70 lakh for the quarter, up 28.2% year on year, and Rs 59,894.26 lakh for the half year, up 32.6%. Group profit after tax rose 86.6% to Rs 5,334.20 lakh and 43.5% to Rs 10,471.40 lakh. Standalone half-year profit included a Rs 4,108.61 lakh exceptional gain. Standalone operating cash flow was negative Rs 790.30 lakh; group operating cash flow was positive Rs 3,569.38 lakh.

Likely market impact

Strong growth supports the stock, but the exceptional gain and negative standalone cash flow are concerns. The new 50.07% promoter may alter strategy.